Artiva Biotherapeutics (ARTV) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $5.85, -3.47% vs the prior close of $6.06.
- Volume 573.14K shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ARTV slides 3.5% to $5.85, a 6-month low. Closed at $5.85, -3.47% vs the prior close of $6.06. Day range $5.82–$6.10, opened at $6.08.
ARTV daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ARTV slides 3.5% to $5.85, a 6-month low
- Closed at $5.85, -3.47% vs the prior close of $6.06. Day range $5.82–$6.10, opened at $6.08.
- Volume was 573.14K shares, 1.4x its 50-day average of 403.73K.
- Price is -37.2% vs its 50-day average ($9.32) and -26.7% vs its 200-day average ($7.98).
- 52-week range $2.75–$14.53; today's close sits at 26% of that range, 59.7% below the 52-week high.
Oct 15, 2026 — ARTV rises 2.5% to $6.06
- Closed at $6.06, +2.54% vs the prior close of $5.91. Day range $5.85–$6.16, opened at $5.93.
- Volume was 478.20K shares, 1.2x its 50-day average of 405.13K.
- Price is -35.8% vs its 50-day average ($9.43) and -24.0% vs its 200-day average ($7.97).
- 52-week range $2.75–$14.53; today's close sits at 28% of that range, 58.3% below the 52-week high.
Oct 14, 2026 — ARTV slides 6.0% to $5.91, a 6-month low, 3 down days in a row
- Closed at $5.91, -6.04% vs the prior close of $6.29. Day range $5.88–$6.25, opened at $6.21.
- Volume was 706.10K shares, 1.8x its 50-day average of 399.24K.
- Price is -38.1% vs its 50-day average ($9.55) and -25.8% vs its 200-day average ($7.96).
- 52-week range $2.71–$14.53; today's close sits at 27% of that range, 59.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ARTV slides 7.1% to $6.29, a 6-month low
- Closed at $6.29, -7.09% vs the prior close of $6.77. Day range $6.24–$6.74, opened at $6.74.
- Volume was 526.70K shares, 1.3x its 50-day average of 400.15K.
- Price is -34.8% vs its 50-day average ($9.65) and -20.9% vs its 200-day average ($7.96).
- 52-week range $2.71–$14.53; today's close sits at 30% of that range, 56.7% below the 52-week high.
Oct 12, 2026 — ARTV dips 2.4% to $6.77, a 6-month low
- Closed at $6.77, -2.45% vs the prior close of $6.94. Day range $6.73–$6.94, opened at $6.92.
- Volume was 248.50K shares, 0.6x its 50-day average of 402.42K.
- Price is -30.5% vs its 50-day average ($9.74) and -14.8% vs its 200-day average ($7.95).
- 52-week range $2.71–$14.53; today's close sits at 34% of that range, 53.4% below the 52-week high.
Oct 9, 2026 — ARTV rises 2.1% to $6.94
- Closed at $6.94, +2.06% vs the prior close of $6.80. Day range $6.77–$7.14, opened at $6.84.
- Volume was 275.90K shares, 0.7x its 50-day average of 401.51K.
- Price is -29.2% vs its 50-day average ($9.80) and -12.5% vs its 200-day average ($7.93).
- 52-week range $2.71–$14.53; today's close sits at 36% of that range, 52.2% below the 52-week high.
Oct 8, 2026 — ARTV dips 2.9% to $6.80
- Closed at $6.80, -2.86% vs the prior close of $7.00. Day range $6.57–$6.92, opened at $6.89.
- Volume was 339.40K shares, 0.8x its 50-day average of 402.58K.
- Price is -31.1% vs its 50-day average ($9.87) and -14.1% vs its 200-day average ($7.92).
- 52-week range $2.71–$14.53; today's close sits at 35% of that range, 53.2% below the 52-week high.
Oct 7, 2026 — ARTV slides 3.7% to $7.00
- Closed at $7.00, -3.71% vs the prior close of $7.27. Day range $6.84–$7.27, opened at $7.10.
- Volume was 324.50K shares, 0.8x its 50-day average of 403.21K.
- Price is -29.6% vs its 50-day average ($9.94) and -11.5% vs its 200-day average ($7.91).
- 52-week range $2.71–$14.53; today's close sits at 36% of that range, 51.8% below the 52-week high.
Oct 6, 2026 — ARTV rises 2.0% to $7.27, 3 up days in a row
- Closed at $7.27, +1.96% vs the prior close of $7.13. Day range $6.92–$7.38, opened at $7.12.
- Volume was 665.40K shares, 1.7x its 50-day average of 395.52K.
- Price is -27.4% vs its 50-day average ($10.01) and -8.0% vs its 200-day average ($7.90).
- 52-week range $2.71–$14.53; today's close sits at 39% of that range, 50.0% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — ARTV jumps 4.4% to $7.13
- Closed at $7.13, +4.39% vs the prior close of $6.83. Day range $6.52–$7.16, opened at $6.75.
- Volume was 473.20K shares, 1.2x its 50-day average of 397.42K.
- Price is -29.2% vs its 50-day average ($10.07) and -9.6% vs its 200-day average ($7.88).
- 52-week range $2.71–$14.53; today's close sits at 37% of that range, 50.9% below the 52-week high.
Oct 2, 2026 — ARTV rises 0.6% to $6.83
- Closed at $6.83, +0.59% vs the prior close of $6.79. Day range $6.74–$7.00, opened at $6.89.
- Volume was 587.60K shares, 1.5x its 50-day average of 390.77K.
- Price is -32.6% vs its 50-day average ($10.13) and -13.2% vs its 200-day average ($7.87).
- 52-week range $2.71–$14.53; today's close sits at 35% of that range, 53.0% below the 52-week high.
ARTV latest news & SEC filings
Every SEC filing by or about ARTV in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Aslan Fred sold 23,463 shares at $7.20 (≈$168.88K) on Oct 6, 2026; now holds 1,519,606
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Horan Christopher sold 10,340 shares at $6.84 (≈$70.70K) on Oct 5, 2026; now holds 312,744
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bush Jennifer sold 8,370 shares at $6.84 (≈$57.23K) on Oct 5, 2026; now holds 366,159
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Banerjee Subhashis sold 1,099 shares at $6.84 (≈$7.51K) on Oct 5, 2026; now holds 169,848
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Aslan Fred sold 61,696 shares at $6.84 (≈$421.83K) on Oct 5, 2026; now holds 1,543,069
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 11, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Aug 14, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$25.00M (prior year -$21.25M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.63 (prior year -$0.87) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 3, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Things to know before you trade ARTV
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 8, 2026, Mar 10, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.54% (largest 9.1%). That is a volatile stock.
- Liquidity: about 470.35K shares (≈$2.75M) trade per day on average.
- 52-week position: $5.85 vs a range of $2.75–$14.53 (26% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Fred Aslan sold 23,429 shares on Sep 8, 2026.
- Latest filings: 8-K Sep 11, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 48.89M shares outstanding (Jul 31, 2026), +100.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
ARTV market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 6.08 | 6.10 | 5.82 | 5.85 | 573.14K |
| Oct 15, 2026 | 5.93 | 6.16 | 5.85 | 6.06 | 478.20K |
| Oct 14, 2026 | 6.21 | 6.25 | 5.88 | 5.91 | 706.10K |
| Oct 13, 2026 | 6.74 | 6.74 | 6.24 | 6.29 | 526.70K |
| Oct 12, 2026 | 6.92 | 6.94 | 6.73 | 6.77 | 248.50K |
| Oct 9, 2026 | 6.84 | 7.14 | 6.77 | 6.94 | 275.90K |
| Oct 8, 2026 | 6.89 | 6.92 | 6.57 | 6.80 | 339.40K |
| Oct 7, 2026 | 7.10 | 7.27 | 6.84 | 7.00 | 324.50K |
| Oct 6, 2026 | 7.12 | 7.38 | 6.92 | 7.27 | 665.40K |
| Oct 5, 2026 | 6.75 | 7.16 | 6.52 | 7.13 | 473.20K |
| Oct 2, 2026 | 6.89 | 7.00 | 6.74 | 6.83 | 587.60K |
| Oct 1, 2026 | 7.11 | 7.15 | 6.77 | 6.79 | 443.70K |
| Sep 30, 2026 | 7.10 | 7.40 | 6.96 | 7.12 | 383.00K |
| Sep 29, 2026 | 7.06 | 7.18 | 6.92 | 7.03 | 450.60K |
| Sep 28, 2026 | 6.91 | 7.18 | 6.75 | 7.05 | 437.50K |
| Sep 25, 2026 | 7.48 | 7.49 | 6.90 | 6.99 | 507.10K |
| Sep 24, 2026 | 7.62 | 7.71 | 7.22 | 7.49 | 511.60K |
| Sep 23, 2026 | 7.99 | 8.20 | 7.52 | 7.72 | 407.70K |
| Sep 22, 2026 | 7.87 | 8.39 | 7.86 | 8.09 | 438.00K |
| Sep 21, 2026 | 8.63 | 8.64 | 7.78 | 7.83 | 629.10K |
About Artiva Biotherapeutics
Artiva Biotherapeutics (ARTV) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1817241.
ARTV board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Fred Aslan | Chief Executive Officer | Sep 15, 2026 |
| Daniel G. Baker | Director | Sep 14, 2026 |
| Brian Daniels | Director | Sep 14, 2026 |
| Elizabeth L Hougen | Director | Sep 14, 2026 |
| Peter Kolchinsky | Director | Sep 14, 2026 |
| Alison Moore | Director | Sep 14, 2026 |
| Capital Management, L.P. Ra | Director | Sep 14, 2026 |
| Capital Healthcare Fund Lp Ra | Director | Sep 14, 2026 |
| Capital Nexus Fund Iii, L.P. Ra | Director | Sep 14, 2026 |
| Capital Nexus Fund, L.P. Ra | Director | Sep 14, 2026 |
| Rajeev M. Shah | Director | Sep 14, 2026 |
| Elaine K. Sorg | Director | Sep 14, 2026 |
| Laura Stoppel | Director | Sep 14, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Fred Aslan | Chief Executive Officer | Sep 15, 2026 |
| Subhashis Banerjee | Chief Medical Officer | Sep 11, 2026 |
| Jennifer Bush | COO, CLO, Compliance Officer | Sep 11, 2026 |
| Christopher Horan | Chief Tech Operations Officer | Sep 11, 2026 |
| Thad Allen Huston | Chief Financial Officer | Mar 10, 2026 |
| Neha Krishnamohan | Chief Financial Officer | Nov 17, 2025 |
| Gines Diego Miralles | President & Head of R&D | Sep 11, 2026 |
| Heather Raymon | SVP, Research and Development | May 19, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 8, 2026 | Fred Aslan | Sale | 23,429 | $10.92 |
| Sep 8, 2026 | Fred Aslan | Sale | 23,429 | $10.92 |
| Sep 8, 2026 | Fred Aslan | Sale | 23,429 | $10.92 |
| Sep 8, 2026 | Fred Aslan | Sale | 23,429 | $10.92 |
| Sep 3, 2026 | Fred Aslan | Sale | 61,888 | $11.16 |
| Sep 3, 2026 | Fred Aslan | Sale | 61,888 | $11.16 |
| Sep 3, 2026 | Fred Aslan | Sale | 61,888 | $11.16 |
| Sep 3, 2026 | Fred Aslan | Sale | 61,888 | $11.16 |
| Sep 3, 2026 | Christopher Horan | Sale | 10,366 | $11.16 |
| Sep 3, 2026 | Christopher Horan | Sale | 10,366 | $11.16 |
| Sep 3, 2026 | Christopher Horan | Sale | 10,366 | $11.16 |
| Sep 3, 2026 | Christopher Horan | Sale | 10,366 | $11.16 |
| Sep 3, 2026 | Subhashis Banerjee | Sale | 1,100 | $11.16 |
| Sep 3, 2026 | Subhashis Banerjee | Sale | 1,100 | $11.16 |
| Sep 3, 2026 | Subhashis Banerjee | Sale | 1,100 | $11.16 |
ARTV financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-83.86M | -3.43 | $-76.75M |
| Dec 31, 2024 | — | $-65.37M | -5.81 | $-55.03M |
| Dec 31, 2023 | $32.92M | $-28.72M | -35.78 | $-47.43M |
Latest balance sheet: total assets $368.63M, total liabilities $21.13M, cash $301.45M (as of Jun 30, 2026).
ARTV earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $11.58 |
| May 8, 2026 | 8-K Item 2.02 (results) | $10.89 |
| Mar 10, 2026 | 8-K Item 2.02 (results) | $6.08 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $3.98 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $2.87 |
| May 8, 2025 | 8-K Item 2.02 (results) | $2.18 |
| Mar 24, 2025 | 8-K Item 2.02 (results) | $3.91 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $13.07 |
| Aug 29, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ARTV
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.